| 1 |
Methodology for constructing scenarios for health policy research: The case of coverage decision-making for drugs for rare diseases in Canada |
|
|
| Conor M.W. Douglas, Dimitra Panagiotoglou, Nick Dragojlovic, Larry Lynd |
|
| Technological Forecasting and Social Change. 2021; 171: 120960 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
A comparative study between ranibizumab and its first biosimilar razumab in terms of efficacy and safety in DME, RVO and wet AMD associated with CNVM |
|
|
| Preethi B, Shilpa G, Dhwani Anil Shah, Praveen R Murthy |
|
| Indian Journal of Clinical and Experimental Ophthalmology. 2021; 7(2): 346 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
STRATEGIES OF EMERGING COUNTRIES TO EXPAND THE OPERATIONS TO THE GLOBAL MARKET OF BIOPHARMACEUTICALS |
|
|
| Ria Christine Siagian, Novilia Bachtiar, Prastuti Soewondo |
|
| INDIAN DRUGS. 2021; 58(06): 07 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Similar biologics in India: A story of access or potential for compromise? |
|
|
| Ramesh Jois, Sukumar Mukherjee, S Rajeswari, PD Rath, Vishal Goyal, Disha Gupta |
|
| Indian Journal of Medical Research. 2020; 152(5): 456 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Biosimilars: Challenges and path forward |
|
|
| Young Sik Kim,Byung Wook Choi,Sung Wook Yang,Seon Mi Shin,Sang Wook Nam,Yun Sook Roh,Jae Young Lee,Kyung Jin Lee,Yong Jick Kim,Jun-Young Kwon,Dong-Il Kim |
|
| Biotechnology and Bioprocess Engineering. 2014; 19(5): 755 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Drug Discovery Research in India: Current State and Future Prospects |
|
|
| Tanjore Balganesh, Tapas K. Kundu, Tushar Kanti Chakraborty, Siddhartha Roy |
|
| ACS Medicinal Chemistry Letters. 2014; 5(7): 724 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Biosimilars in Oncology: From Development to Clinical Practice |
|
|
| Katherine H. Rak Tkaczuk,Ira Allen Jacobs |
|
| Seminars in Oncology. 2014; 41: S3 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Biosimilar Insulins Are Coming: What They Are, What You Need To Know |
|
|
| Steven Edelman,William H. Polonsky,Christopher G. Parkin |
|
| Current Medical Research and Opinion. 2014; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
Comparison of global regulatory approvals for Biosimilar products |
|
|
| Konangi, S., Raviteja, M.N., Vishal Gupta, N. |
|
| International Journal of PharmTech Research. 2013; 5(3): 924-935 |
|
| [Pubmed] [Google Scholar] |
|
| 10 |
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics |
|
|
| Devlin, S.M., Bressler, B., Bernstein, C.N., Singh, H., Feagan, B.G. |
|
| Canadian Journal of Gastroenterology. 2013; 27(10): 567-271 |
|
| [Pubmed] [Google Scholar] |
|
| 11 |
Biosimilars in IBD: Hope or expectation? |
|
|
| Gecse, K.B., Khanna, R., Van Den Brink, G.R., Feagan, B.G., DæHaens, G.R.A.M. |
|
| Gut. 2013; 62(6): 803-807 |
|
| [Pubmed] [Google Scholar] |
|
| 12 |
Special characteristics and risk management of biologicals and biosimilars |
|
|
| Shi, S., Chen, D. |
|
| Pharmaceutical Care and Research. 2012; 12(5): 326-329+386 |
|
| [Pubmed] [Google Scholar] |
|
| 13 |
Biosimilar DMARD in rheumatology: A general perspective with focus on India |
|
|
| Arvind Chopra,Subramanian Shankar |
|
| Indian Journal of Rheumatology. 2012; 7(2): 89 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 14 |
Biosimilars in rheumatology; the new kid in the block: Panacea or pandoras box? |
|
|
| Krishnan Shanmuganandan,Darshan S. Bhakuni |
|
| Indian Journal of Rheumatology. 2012; 7(2): 67 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
